Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: Sharck who wrote (1051)	10/7/2000 4:52:13 PM
From: Sharck	Read Replies (1) \| Respond to of 1321

Short sighted analysis? Ever since Visudyne, QLTIs treatment for wet age-related macular degeneration hit the shelves, analysts have gone mad over the stock. finance.yahoo.com QLTI has said expected revs will reach US$60 million by 2004. However Leerink Swann & Co. said this week its research shows that fewer than 20% of patients are candidates for this drug. If correct, estimates will have to be revised to $350 million. Not the stock has been hit already dropping from a high of 85... Expect some more volatility and upside in the near future.